{"title":"ravulizumab治疗阵发性夜间血红蛋白尿症（PNH）患者的严重急性呼吸系统综合征冠状病毒2型感染：一例报告","authors":"P. Estival, B. Colás, Yang Dai, F. González","doi":"10.32440/AR.2020.137.03.CC01","DOIUrl":null,"url":null,"abstract":"The clinical course of a Paroxysmal Nocturnal Hemoglobinuria (PNH) patient receiving treatment with terminal complement by ravulizumab and SARS-CoV2 infection is described.\nThe treatment commenced in January 2016 showing adequate tolerance and symptom resolution.\nIn April 2020 an episode of breakthrough hemolysis is observed. Chest X-Ray revealed a right infection lobar infiltrate with SARS-CoV-2 positive PCR. The patient was afebril with normal oxygen saturation. He did not require standard disease treatment and presented eventual resolution, developing only mild symptoms.\nNeither PNH nor ravulizumab treatment seem to influence susceptibility to Covid-19 infection. It is possible that razulizumab, a complement inhibitor, may have played a beneficial role in the favorable clinical development.","PeriodicalId":75487,"journal":{"name":"Anales de la Real Academia Nacional de Medicina","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"SARS-CoV-2 Infection in a patient with paroxysmal nocturnal haemoglobinuria (PNH) Treated with ravulizumab: a case report\",\"authors\":\"P. Estival, B. Colás, Yang Dai, F. González\",\"doi\":\"10.32440/AR.2020.137.03.CC01\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The clinical course of a Paroxysmal Nocturnal Hemoglobinuria (PNH) patient receiving treatment with terminal complement by ravulizumab and SARS-CoV2 infection is described.\\nThe treatment commenced in January 2016 showing adequate tolerance and symptom resolution.\\nIn April 2020 an episode of breakthrough hemolysis is observed. Chest X-Ray revealed a right infection lobar infiltrate with SARS-CoV-2 positive PCR. The patient was afebril with normal oxygen saturation. He did not require standard disease treatment and presented eventual resolution, developing only mild symptoms.\\nNeither PNH nor ravulizumab treatment seem to influence susceptibility to Covid-19 infection. It is possible that razulizumab, a complement inhibitor, may have played a beneficial role in the favorable clinical development.\",\"PeriodicalId\":75487,\"journal\":{\"name\":\"Anales de la Real Academia Nacional de Medicina\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anales de la Real Academia Nacional de Medicina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32440/AR.2020.137.03.CC01\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anales de la Real Academia Nacional de Medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32440/AR.2020.137.03.CC01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
SARS-CoV-2 Infection in a patient with paroxysmal nocturnal haemoglobinuria (PNH) Treated with ravulizumab: a case report
The clinical course of a Paroxysmal Nocturnal Hemoglobinuria (PNH) patient receiving treatment with terminal complement by ravulizumab and SARS-CoV2 infection is described.
The treatment commenced in January 2016 showing adequate tolerance and symptom resolution.
In April 2020 an episode of breakthrough hemolysis is observed. Chest X-Ray revealed a right infection lobar infiltrate with SARS-CoV-2 positive PCR. The patient was afebril with normal oxygen saturation. He did not require standard disease treatment and presented eventual resolution, developing only mild symptoms.
Neither PNH nor ravulizumab treatment seem to influence susceptibility to Covid-19 infection. It is possible that razulizumab, a complement inhibitor, may have played a beneficial role in the favorable clinical development.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
